Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 6.30M -50.5% |
| Revenue (ttm) | 19.57M +33.8% |
| Net Income | -24.99M |
| EPS | -2.12 |
| Shares Out | 13.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400,619 |
| Open | 0.4834 |
| Previous Close | 0.4983 |
| Day's Range | 0.4450 - 0.5083 |
| 52-Week Range | 0.3830 - 7.9500 |
| Beta | 6.12 |
| Analysts | Buy |
| Price Target | 2.45 (+440.6%) |
| Earnings Date | Aug 18, 2026 |
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its a... [Read more]
Financial Performance
In 2025, Vivos Therapeutics's revenue was $17.44 million, an increase of 16.05% compared to the previous year's $15.03 million. Losses were -$21.17 million, 90.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price target is $2.45, which is an increase of 440.60% from the latest price.
News
Vivos Therapeutics says Vida oral appliance improves insomnia in study
Vivos Therapeutics (VVOS) announced compelling clinical data showing that treatment with its FDA-cleared Vida oral appliance led to statistically significant improvement in insomnia severity in 100% o...
Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatmen...
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos and Streeterville Extend Timeframe of Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics intends to file registration statement for rights offering
Vivos Therapeutics (VVOS) announced that it intends to file a registration statement with the U.S. SEC for a proposed rights offering pursuant to which the company would distribute, as a…
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatmen...
Vivos Therapeutics enters pact with South Palm Cardiovascular Associates
Vivos Therapeutics (VVOS) announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates to support the formation and operation of AIM Florida, a physician-alig...
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics Transcript: WTR Insights Conference: Powered by The Small Cap Showcase
A scalable, capital-light model for treating sleep apnea is driving rapid growth, leveraging collaborations with cardiology and sleep centers. High margins, strong insurance coverage, and a proven management team support national expansion, with execution now the key focus.
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme...
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)
Reports Q1 revenue $5.14M, consensus $4.35M. Kirk Huntsman, Vivos’ chairman and CEO, stated “Our significant revenue increase year over year and quarter over quarter confirms what we emphatically stat...
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 202...
Vivos Therapeutics Quarterly report: Q1 2026
Vivos Therapeutics has published its Q1 2026 quarterly earnings report on May 20, 2026.
Vivos Therapeutics Earnings release: Q1 2026
Vivos Therapeutics released its Q1 2026 earnings on May 20, 2026, summarizing the period's financial results.
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Vivos Therapeutics Registration statement: Registration filing
Vivos Therapeutics filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vivos Therapeutics (VVOS) to $2.50 from $7 and keeps a Buy rating on the shares following the 2025 earnings report. The firm…
Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global
Alliance Global lowered the firm’s price target on Vivos Therapeutics (VVOS) to $1.75 from $2.50 and keeps a Neutral rating on the shares. Vivos Therapeutics reported Q4 results that were…
Vivos Therapeutics Earnings Call Transcript: Q4 2025
Revenue grew 16% in 2025, driven by SCN acquisition and a shift to a medical provider model, offsetting legacy declines. Gross margin held at 60%, but net loss widened due to integration costs. Expansion, insurance access, and SO team deployment are expected to drive growth in 2026.
Vivos Therapeutics Earnings release: Q4 2025
Vivos Therapeutics released its Q4 2025 earnings on April 15, 2026, summarizing the period's financial results.
Vivos Therapeutics Annual report: Q4 2025
Vivos Therapeutics has published its Q4 2025 annual report on April 15, 2026.
Vivos Therapeutics Reports Full Year 2025 Financial Results
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call t...
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme...
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme...
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare